Phase 2 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with prostate cancer (a specific type called adenocarcinoma), confirmed by a laboratory test.
- People who had a biopsy with at least 10 tissue samples taken, with each sample examined separately to identify exactly where the cancer is located.
- People whose biopsy results show a cancer grade of Gleason 7 or higher (grade group 2 or above), indicating a moderate to high aggressiveness level.
- People who are planning to have their prostate surgically removed.
- People who are willing to follow their usual diet with the possible addition of 2 ounces of walnuts per day.
- People who can read, write, and understand English.
- People aged 18 or older.
Who may not be able to join:
- People who have a nut allergy.
- People who have previously received hormone therapy or anti-androgen therapy for prostate cancer.
- People who have used a type of medication called 5-alpha reductase inhibitors in the past 6 months (confirm with trial site for specific drug names).
- People who have previously had radiation treatment or a freezing treatment directed at the prostate.
- People who are currently following a modified diet or weight loss program, or who are taking supplements containing omega-3s (such as fish oil).
- People who currently have another active cancer, with the exception of certain common skin cancers (basal cell or squamous cell carcinoma).
- People who have significant other health conditions — such as serious heart, lung, or liver disease, alcohol or drug addiction, or conditions affecting how the body absorbs nutrients — that the study doctor considers would make participation unsuitable.
- People who have psychological or mental health conditions that could affect their ability to give informed consent or follow the study requirements.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Stephen Freedland, MD, Cedars-Sinai Medical Center
Phone: 310-423-0333
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Mean difference in prostatic tissue Ki67 expression from baseline biopsy to RP
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.